Roche has parted with $1.4 billion upfront to secure rights to an obesity candidate developed by Zealand Pharma, taking its tally of weight-loss candidates in clinical development to five.

Zealand Pharma has suffered another setback in its ... which is already in late-stage development for obesity. The two studies are LIVERAGE in adults with MASH and moderate or advanced fibrosis ...

On World Health Day,a 31 country Ipsos Health Service Report 2024 showsthe health concernsbothering Indians most were ...

Find insight on Fisher & Paykel Healthcare, Hims & Hers, GSK and more in the latest Market Talks covering health care.

Apr. 8, 2025 — New research has uncovered a surprising culprit underlying cardiovascular diseases in obesity and diabetes -- not the presence of certain fats, but their suppression. The study ...

The study evaluated setmelanotide, a melanocortin-4 receptor (MC4R) agonist, for the treatment of acquired hypothalamic obesity, a condition characterized by rapid, severe weight gain due to ...

4 April 2025 A planned autumn review of the UK’s 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG) will be brought forward to report back in June, it has been announced.

Tracks the performance of pharmaceutical companies in India, comprising leading pharmaceutical stocks listed on the National Stock Exchange (NSE), reflecting trends in the pharmaceutical sector.